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Background: Fibulin-4, a member of the fibulin family of extracellular glycoproteins, is implicated in the
progressions of some cancers. However, no information has been available to date regarding the function of
fibulin-4 in ovarian carcinoma progression.
Methods: In this study, fibulin-4 mRNA and protein expression in normal ovarian tissue, ovarian tumor, high
invasive subclones and low invasive subclones were evaluated by immunohistochemistry and real time reverse
transcriptase-polymerase chain reaction (RT-PCR). The serum levels of fibulin-4, cancer antigen 125 (CA-125)
and cerbohydrate antigen 199 (CA19-9) in patients with ovarian tumor were measured by enzyme-linked
immunosorbent assay and electrochemiluminescent immunoassay. To assess the angiogenic properties of
fibulin-4, vascular endothelial growth factor (VEGF) expression and tumor microvessel density were analyzed
in ovarian carcinoma by immunohistochemistry.
Results: Fibulin-4 expression was upregulated in ovarian carcinoma, and positively correlated with MVD and
VEGF expression. Fibulin-4 overexpression was significantly associated with advanced stage, low differentiation,
lymph node metastasis and poor prognosis in patients with ovarian cancer. The serum levels of fibulin-4,
CA-125 and CA19-9 in patients with ovarian carcinoma were much higher than those with benign ovarian
tumors and normal controls. Compared to CA-125 and CA19-9, fibulin-4 had better diagnostic sensitivity and
specificity.
Conclusions: Fibulin-4 is a novel gene that is found overexpressed in ovarian cancer and associated with poor
prognostic clinicopathologic features. This study shows that fibulin-4 may serve as a new prognostic factor and
as a potential therapeutic target for patients with ovarian cancer in the future.
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Ovarian cancer is one of the most aggressive and hetero-
geneous cancer types in women and one of the leading
causes of gynaecological deaths [1,2]. Its high mortality
is attributable to the fact that the majority of ovarian
cancer patients are diagnosed at advanced stages when
conventional therapy is less effective [3]. Although
substantial advances have been made in ovarian cancer
research, the overall 5-year survival rate is still less
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unless otherwise stated.considered the major reasons for poor clinical outcome
and cancer deaths [5]. Therefore, studying the mechan-
ism of tumor invasion and metastasis will provide
further insights into the development and progression
of ovarian cancer. In recent years, many biomarkers
have been investigated which are involved in the pro-
gression of ovarian cancer [6]. But few studies have
been done to assess the functions of fibulin-4 in ovar-
ian cancer development.
Fibulin-4, also known as endothelial growth factor
(EGF)-containing fibulin-like extracellular matrix pro-
tein 2 (EFEMP2), mutant p53 binding protein 1
(MBP1), or UPH1, is a 443 amino acid secreted protein
that contains six EGF-like calcium-binding domains
and belongs to the fibulin family [7]. Fibulins havehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hesion and motility, and are closely associated with the
development of a wide variety of carcinomas [8]. As
tumor suppressor genes, fibulin-2 [9,10] and fibulin-5
[11-13] were widely considered to be associated with
the suppression of tumor growth, invasion, and angio-
genesis. The research findings on the role of fibulin-1
and fibulin-3 in different tumor tissues have been
controversial. Few researchers reported oncogenic
activities [14-20], whereas others have reported tumor-
suppressive activities [21-28]. This discrepancy may be
attributable to the influence of the tumor microenvir-
onment on tumor-associated genes in promoting
angiogenesis and metastasis [29].
Fibulin-4 is essential for connective tissue development
and elastic fiber formation and may also play an import-
ant role in vascular patterning and collagen biosynthesis
[30]. Fibulin-4 plays a role in many clinical conditions
such as cutis laxa [31], aortic aneurysms [32], osteo-
arthritis [33], and cancer [34,23]. In the study on colon
tumors [34], Gallagher et al. found that the fibulin-4 gene
was localized on chromosome 11q13; translocations,
amplifications, and other rearrangements in this region
are associated with a variety of human cancers [35,36].
Reverse transcriptase (RT)-polymerase chain reaction
(PCR) of RNA from paired human colon tumors and ad-
jacent normal tissue showed that tumors had a 2–7 fold
increase in the level of fibulin-4 mRNA expression [34].
However, in prostate cancer [23], fibulin-4 is significantly
downregulated and is weakly expressed in carcinoma cell
lines compared to normal prostate epithelial cells.
Against this background of controversies in the research
addressing the role of fibulin-4, more studies are needed
to elucidate the relationship between fibulin-4 and can-
cer. To our knowledge, the role of fibulin-4 in cervical
cancer remains unexplored.
The purpose of this study was to assess whether
fibulin-4 expression was associated with the progression
of ovarian cancer, and further to investigate the relation-
ship between fibulin-4 and angiogenesis.
Methods
Cell lines
Highly invasive subclones (S1, A1) and low invasive sub-
clones (S21, A19) were derived from the SKOV3 and
3AO human ovarian cancer cell lines, using the limited
dilution method. Next, the cell electrophoretic mobility
(EPM) of each clone was measured to study the charge-
related properties using microcapillary electrophoresis
chips according to Omasu’s methods [37]. Finally, the
MTT assay, soft agar colony formation assay, matrigel
invasion assay, and cell migration assay were performed
and tumor xenografts were generated in nude mice to
confirm that high invasive subclones and low invasivesubclones had high and low metastatic potential, re-
spectively [38]. Cells were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS) and
antibiotics (Gibco BRL, Rockville, MD).
Tissue specimens
A total of 260 human ovarian tissue specimens ob-
tained with written informed consent from patients
were used for this study. Two hundred and twenty
(220) epithelial ovarian tumors were enrolled from the
Department of Gynecology and Obstetrics, Shandong
Provincial Hospital between 2005 and 2011. There
were 60 benign ovarian tumors that contain 25 serous
cystadenoma, 22 mucinous cystadenoma and 13 endo-
metrioid tumor (age range, 20–45 years; mean [SD], 35
[6] years) and 160 epithelial ovarian carcinomas that
contain 58 serous cystadenocarcinoma, 56 mucinous
cystadenocarcinoma and 46 endometrioid carcinoma
(age range, 28–65 years; mean [SD], 42 [8] years). All
ovarian cancer patients were clinically staged accord-
ing to the International Federation of Gynecology and
Obstetrics (FIGO) staging system (FIGO stage I, 36
cases; FIGO stage II, 38 cases; and FIGO stage III, 46
cases; and FIGO stage IV, 40 cases). None of the ovar-
ian cancer patients received preoperative radiation or
chemotherapy. All patients were treated consecutively
and were followed up regularly; 5 patients were lost to
follow-up and 20 patients died during the study period.
Follow-up duration was between 1 to 7 years by the
end of 2012. Forty normal ovary tissue specimens (age
range, 25–65 years; mean [SD], 45 [7] years) were obtained
from the Department of Gynecology and Obstetrics,
Shandong Provincial Hospital. The study was approved by
the Institutional Medical Ethics Committee of Shandong
University.
Blood samples
Blood samples were accordingly obtained with the written
informed consent from the same 220 ovarian tumor
patients that contain 60 benign ovarian tumors and
160 epithelial ovarian carcinomas at the Department of
Gynecology and Obstetrics, Shandong Provincial Hospital
between 2005 and 2011. None of the ovarian cancer pa-
tients received preoperative radiation or chemotherapy.
Blood samples were collected before the initiation of treat-
ment and centrifuged at 1500 g for 10 minutes. Aliquots
of the separated plasma were stored at −80°C for future
analysis. Forty control blood samples were obtained with
the written informed consent from age-matched exam-
inees undergoing health examinations at Shandong
Provincial Hospital. Control subjects had no history of
disease and no abnormalities on laboratory examina-
tions. The study was approved by the Institutional
Medical Ethics Committee of Shandong University.
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Levels of fibulin-4 in serum samples were measured
using sandwich enzyme-linked immunosorbent assay
(ELISA) with human fibulin-4 ELISA assay kits
(Immuno-Biological Laboratories, Japan). Serum was
diluted with Enzyme ImmunoAssay (EIA) buffer (1%
BSA, 0.05% Tween 20 in phosphate buffer) and incu-
bated for 2 hour at 37°C. After 4 washes with EIA
buffer, horse radish peroxidase-conjugated antibodies
were added and incubated for 30 minutes at 4°C. AfterFigure 1 Expressions of fibulin-4 in human ovarian tissues. (A) The ep
human ovarian, (C, D) Benign ovarian tumor, (E) High differentiation of ova
(G) Low differentiation of ovarian carcinoma. (Magnification × 200).washed 4 times, 100 μl of tetramethyl benzidine solution
was added and incubated for 30 minutes at room
temperature. The reaction was stopped with 100 μl of 1 N
sulfuric acid and measured using the ELISA reader at
450 nm.
Quantitative analysis of CA-125 and CA19-9
Serum CA-125 and CA19-9 were detected using the elec-
trochemiluminescent immunoassay (ECLIA) method. The
ECLIA kits were provided by Roche Diagnosticsithelial cells of normal human ovarian, (B) the stroma of normal
rian carcinoma, (F) Medium differentiation of ovarian carcinoma,
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luminescent analyzer was used as the instrument with
20 μl per serum sample.
Immunohistochemistry (IHC)
According to the standard streptavidin-biotin-peroxidase
complex procedures, immunohistochemistry (IHC)
was performed on formalin-fixed, paraffin-embedded
sections (5 μm thick) and cell slides were fixed in 4%
paraformaldehyde. Briefly, after dewaxing, rehydration,
and antigen retrieval, the sections were incubated with
rabbit anti-human fibulin-4 monoclonal antibody
(ab125073, Abcam) with working dilutions of 1: 200 at
4°C overnight. Human breast cancer paraffin-embedded
sections (fibulin-4 positive) were used as positive
controls. A negative control was obtained by replacing
the primary antibody with normal rabbit immuno-
globulin (IgG). Positive expression of fibulin-4 protein
was defined as the presence of brown granules in the
cytoplasm.
Immunohistochemistry (IHC) analysis
A semiquantitative scoring system derived from the
method by Soumaoro [39] for both the intensity of
staining and the percentage of positive cells was usedTable 1 Protein expression of fibulin-4 in human ovarian tissu
N Fibulin-4 low (−/+)
n %
Normal 40 37 92.5%
Benign 60 40 66.7%
Pathology type
Serous cystadenoma 25 16 64%
Mucinous cystadenoma 22 15 68.2%
Endometrioid tumor 13 9 69.2%
Carcinoma 160 45 28.1%
Pathology type
Serous cystadenocarcinoma 58 16 27.6%
Mucinous cystadenocarcinoma 56 14 25%
Endometrioid carcinoma 46 15 32.6%
Cell differentiation
High and Medium 88 41 46.6%
Low 72 4 5.6%
Tumor stage
Low stage 74 34 45.9%
High stage 86 11 12.8%
Nodal status
Positive 83 8 9.6%
Negative 77 41 53.2%to evaluate fibulin-4 expression. The intensity of
fibulin-4 positive staining was scored from 0 to 3
(negative = 0, weak = 1, moderate = 2, or strong = 3)
and the percentage of positively stained cells was
scored as 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%),
and 4 (76–100%). The sum of the intensity and per-
centage scores was used as the final staining scores (0
to 7). The sum-indexes (−), (+), (++), and (+++) indi-
cated final staining scores of 0, 1–3, 4–5, and 6–7,
respectively. For statistical analysis, sum-indexes (−)
and (+) were defined as low fibulin-4 expression, while
sum-indexes (++) and (+++) were defined as high
fibulin-4 expression. Each section was independently
scored by three pathologists. To assess reproducibility,
we invited three other pathologists to score all sections
independently. The interobserver reliability and intraob-
server reproducibility of IHC experiments were evaluated
by kappa statistic evaluation.Microvessel assessment
Microvessel density (MVD) was assessed according to
CD31 immunohistochemical staining of tumor ves-
sels. Any immune-positive single endothelial cell or
endothelial cell clusters and microvessels in the
tumor were considered to be individual vessels andes
Fibulin-4 high (++/+++) X2 P
n %




















Table 2 mRNA expression of fibulin-4 in human ovarian
tissues
N Fibulin-4 mRNA P
Control 40 0.0089 ± 0.0047
Benign 60 0.0092 ± 0.0054 >0.05
Pathology type >0.05
Serous cystadenoma 25 0.0091 ± 0.0058
Mucinous cystadenoma 22 0.0098 ± 0.0067
Endometrioid tumor 13 0.0084 ± 0.0035
Carcinoma 16 0.0947 ± 0.0083 <0.05
Pathology type 0 >0.05
Serous cystadenocarcinoma 58 0.0872 ± 0.0097
Mucinous cystadenocarcinoma 56 0.0913 ± 0.0108
Endometrioid carcinoma 46 0.0894 ± 0.0087
Cell differentiation <0.05
High and Medium 88 0.0257 ± 0.0084
Low 72 0.0968 ± 0.0113
Tumor stage <0.05
Low stage 74 0.0284 ± 0.0075
High stage 86 0.0895 ± 0.0118
Nodal status <0.05
Positive 83 0.0983 ± 0.0094
Negative 77 0.0309 ± 0.0081
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Peritumoral vascularity, vascularity in areas of necro-
sis and vessels with a thick muscle wall or in a diam-
eter larger than eight erythrocytes, was not counted.
The sections were scanned at low power (100×) to se-
lect the most vascularized (hot-spots) areas. The
microvessels in the hot-spots were then counted, and
an average count in three hot spots was calculated as
the MVD. All counts were made independently by
three observers who were blinded to the correspond-
ing clinicopathologic data.
Quantitative real-time-polymerase chain reaction
Total RNA was extracted using Trizol reagent (Invitrogen)
and reverse transcribed. Quantitative real-time PCR
analysis was performed using ABI PRISM 7500 Real-
Time PCR System (Applied Biosystems). Each well
(20 μl reaction volume) contained 10 μl Power SYBR
Green PCR master mix (Applied Biosystems), 1 μl of
each primer (5 μmol/l) and 1 μl template. The following
primers were used:





Cells were lysed by using RIPA buffer containing 1 mM
PMSF. Fifty microgram of protein per lane was
resolved by SDS-PAGE and transferred to PVDF
membrane and blocked with 5% BSA. After incubating
with primary antibody to goat human fibulin-4 and
VEGF overnight at 4°C and horseradish peroxidase-
conjugated anti-goat IgG as secondary antibody for
1 hour at room temperature, blots were developed
using ECL method. Band intensity was analyzed using
Gel-Pro Analyzer Software (Media Cybernetics, Inc.,
Bethesda, MD).
Statistical analysis
IHC data were analyzed using the chi-square test.
Measurement data were expressed as the mean ± SE.
The interobserver reliability and intraobserver repro-
ducibility of IHC experiments were evaluated using
kappa statistic evaluation. The strength of agreement
was interpreted as follows: excellent (kappa ≥ 0.80),
good (0.60–0.79), moderate (0.40–0.59), poor (0.20–0.39),
and very poor (<0.20) [41]. For comparison of means be-
tween two groups, a two-tailed t-test was used and for
comparison of means among three groups, one-way
ANOVA was used. Survival curves were calculated using
the Kaplan-Meier method and analyzed using the log-
rank test. Correlations of fibulin-4 expression with VEGFexpression and MVD were analyzed using the Pearson
correlation test. Multivariate Cox proportional hazard
models were used to define the potential prognostic
significance of individual parameters. Receiver-operating
characteristic (ROC) curve was performed and the area
under the curve (AUC) was calculated separately to test
the sensitivity and specificity of all three biomarkers. The
value of AUC is between 0.5 and 1, and the diagnostic ac-
curacy was interpreted as follows: good (AUC ≥ 0.90),
moderate (0.70–0.89) and poor (0.50–0.69). Statistical
analysis was performed using SPSS software version 13.0.
Two-sided p values of <0.05 were considered statistically
significant.
Results
Fibulin-4 expression in human ovarian tissues
As shown in Figure 1, in normal human ovarian surface
epithelial cells, fibulin-4 protein expression was very low
(Figure 1A), and in the ovarian stroma, fibulin-4 protein
expression was mainly focused around the vasculatures
(Figure 1B). However in most ovarian carcinomas,
fibulin-4 immunoreactivity was high, and high fibulin-4
protein expression was found in the cytoplasm of ovar-
ian cancer cells (Figure 1E,F,G). Moreover, high fibulin-4
protein expression was associated with low differenti-
ation, advanced stage and positive lymph node status of
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ity coefficients were 0.84 and 0.87 for the first and sec-
ond assessments, with an intraobserver reproducibility
coefficient of 0.86. The interobserver reliability and
intraobserver reproducibility of IHC experiments were
excellent. Similar results were also shown in the real
time RT-PCR experiment, fibulin-4 mRNA expressionFigure 2 Kaplan-Meier analysis and VEGF expressions in highly invasi
invasive cancer were included in the cohort. Patients with high EFEMP1 ex
with low EFEMP1 expression (blue line, n = 45). (B) Fibulin-4 mRNA express
S21 and A19 as measured by q-RT-PCR. (C) Fibulin-4 protein expressions of
ICC staining (Magnification × 200). (D) Fibulin-4 protein expressions of high
Western blot. *P < 0.05 versus control.was also very low in normal ovarian tissues and benign
ovarian tumors, and significantly high fibulin-4 expres-
sion was seen in ovarian carcinoma. Moreover, high
fibulin-4 mRNA expression was also associated with low
differentiation, advanced stage and positive lymph node
status of ovarian carcinomas (Table 2). To evaluate the
prognostic value of fibulin-4 in ovarian cancer, weve subclones and low invasive subclones. (A) 160 patients with
pression (green line, n = 115) had a much worse prognosis than those
ions of highly invasive subclones S1 and A1 and low invasive subclones
highly invasive subclones and low invasive subclones as measured by
ly invasive subclones and low invasive subclones as measured by
Chen et al. BMC Cancer  (2015) 15:91 Page 7 of 12performed survival analysis using Kaplan-Meier analysis.
The result showed that patients with high fibulin-4 ex-
pression had a much worse prognosis than those with
low fibulin-4 expression (log rank, P < 0.01; Figure 2A).
In multivariate analysis, considering all histological and
molecular features together, the important prognostic
factors were fibulin-4 expression (P = 0.000; hazard ratio
2.129), lymph node metastasis (P = 0.001; hazard ratio
1.017), and tumor stage (P = 0.005; hazard ratio 1.984)
(Table 3).
Different expression of fibulin-4 and VEGF in the highly
invasive subclone and low invasive subclone
The highly invasive subclone (S1 and A1) and the low
invasive subclone (S21 and A19) were derived from the
SKOV3 and 3AO human ovarian cancer cell lines, using
the limited dilution method. Since the cell lines have
had similar genetic backgrounds, they are suitable for
comparative analysis. As shown in Figure 2B,C,D and
Figure 3, the protein and mRNA expressions of fibulin-4
and VEGF were much higher in highly invasive sub-
clones (S1 and A1), compared to the low invasive sub-
clones (S21 and A19).
Serum levels of fibulin-4, CA-125 and CA19-9 in human
ovarian tumor patients and healthy controls
As shown in Table 4, the serum levels of fibulin-4, CA-
125 and CA19-9 in patients with ovarian carcinoma was
much higher than that with benign ovarian tumor and
healthy controls (P < 0.05). No significant difference was
found between healthy control and benign ovarian
tumor (P >0.05). Moreover, high serum levels of fibulin-4,
CA-125 and CA19-9 were associated with low differenti-
ation, advanced stage and positive lymph node status of
ovarian carcinomas (P < 0.05). There were no significant
differences in the serum levels of fibulin-4 among different
pathology types of ovarian carcinoma (P >0.05). However,
the serum level of CA-125 was increased in serous
cystadenocarcinoma and CA19-9 was increased in mu-
cinous cystadenocarcinoma (P < 0.05). The serum levels
of fibulin-4, CA-125 and CA19-9 were evaluated byTable 3 Predictive factors of survival by multivariate
analysis (Cox proportional hazards model)
Prognostic factors Hazard ratio (95% CI) P
Fibulin-4 3.573(2.033, 6.282) 0.000
Pathology type 1.263(0.593, 2.689) 0.545
Cell differentiation 1.095(0.986, 1.216) 0.089
Tumor stage 1.984(1.236, 3.185) 0.005
Lymph node metastasis 1.017(1.007, 1.027) 0.001
Tumor size 1.012(0.999, 1.026) 0.065
Age 1.263(0.593, 2.689) 0.545ROC analysis (Figure 4). The AUC of fibulin-4, CA-125
and CA19-9 were 0.883, 0.808 and 0.701, suggesting
that clinical usefulness of the three biomarkers for diag-
nosing ovarian carcinoma was moderate. The Youden
index [42] identified the cut-off level of fibulin-4 was
45.79 ng/ml, with a sensitivity of 75.0% and a specificity
of 84.0%. Table 5 shows the comparisons of sensitivity,
specificity, positive predictive value, negative predictive
value, positive likelihood ratio and negative likelihood
ratio among the three markers. In combined measure-
ments, when 2 markers were both determined in diag-
nosis of ovarian cancer, combination of fibulin-4 and
CA-125 was superior to other two combinations. When
combined fibulin-4, CA-125 and CA19-9, the diagnostic
specificity, positive predictive value and positive likeli-
hood ratio were all significantly increased.
Relationships of fibulin-4 with VEGF expression and MVD
Figure 5 shows the representative immunohistochemical
staining images of VEGF and CD34. The immunohisto-
chemical expressions of VEGF and fibulin-4 were evalu-
ated with software Imag Pro Plus 6.0 to detect the
photodensity. In brief, five positive fields in a section
were selected at random and then read using Imag Pro
Plus 6.0, finally the average densities were calculated.
Pearson correlation tests of MVD (Figure 6A, P < 0.01)
and VEGF expression (Figure 6B, P < 0.01) versus
fibulin-4 revealed strong positive correlations.
Discussion
In the present study, we have demonstrated for the first
time that the expression of fibulin-4 is associated with
poor prognostic clinicopathologic features, neovasculari-
zation, and poor outcomes in human ovarian carcinomas.
Our immunohistochemical studies showed an up-
regulation of fibulin-4 expression in ovarian carcinoma
tissues, compared with normal ovarian tissues and be-
nign ovarian tumors. Real time PCR results confirmed
that mRNA expression of fibulin-4 was also up-regulated
in ovarian carcinoma tissues. Moreover, high fibulin-4
expression was associated with low differentiation, high
stage and positive lymph node status in ovarian carcin-
omas. Similar results have been reported in earlier studies
on colon cancer; dysregulated expression of the fibulin-4
gene was shown to be associated with human colon
tumourigenesis [34]. However, contrasting results have
also been reported for prostate cancer. By microarray ana-
lysis, the fibulin-4 genes were significantly down-regulated
in prostate cancer and this result was corroborated by
quantitative RT-PCR [35]. In our study, fibulin-4 was
overexpressed in ovarian carcinomas and was shown to
play an important role in tumor development. As is the
case for other fibulins, there are controversies in research
on fibulin-4; these discrepancies may be attributable to
Figure 3 Fibulin-4 expressions in highly invasive subclones and low invasive subclones. (ABCD) Fibulin-4 protein expressions of highly
invasive subclones S1 (A) and A1 (B) and low invasive subclones S21 (C) and A19 (D) as measured by ICC staining (Magnification × 200).
(E) Fibulin-4 mRNA expressions of highly invasive subclones and low invasive subclones as measured by q-RT-PCR. (F) Fibulin-4 protein
expressions of highly invasive subclones and low invasive subclones as measured by Western blot. *P < 0.05 versus control.
Chen et al. BMC Cancer  (2015) 15:91 Page 8 of 12the fact that the tumor microenvironment influences the
functions of tumor-associated genes [29].
Angiogenesis is the process of formation of new
microvessels from preexisting vasculature. Once thetumor volume exceeds a few millimeters in diameter,
hypoxia and nutrient deprivation trigger tumor cells to
exploit their microenvironment by releasing cytokines
and growth factors, which then activate normal,
Table 4 Serum levels of fibulin-4, CA-125 and CA19-9 in patients with ovarian tumor
N Fibulin-4(ng/ml) P CA-125(U/ml) P CA19-9(U/ml) P
Control 40 29.54 ± 16.17 33.32 ± 24.55 35.67 ± 15.59
Benign 60 38.15 ± 18.43 >0.05 33.16 ± 16.23 >0.05 34.89 ± 17.26 >0.05
Pathology type >0.05 >0.05 >0.05
Serous cystadenoma 25 37.26 ± 12.54 30.51 ± 10.83 36.85 ± 16.27
Mucinous cystadenoma 22 36.75 ± 14.32 35.24 ± 12.69 33.92 ± 14.78
Endometrioid tumor 13 39.26 ± 19.73 32.76 ± 15.93 31.61 ± 13.41
Carcinoma 160 267.06 ± 238.71 <0.05 231.60 ± 205.47 <0.05 158.21 ± 124.59 <0.05
Pathology type >0.05 <0.05 <0.05
Serous cystadenocarcinoma 58 273.65 ± 215.87 366.22 ± 216.54 97.32 ± 31.13
Mucinous cystadenocarcinoma 56 259.68 ± 211.69 144.38 ± 95.53 275.63 ± 107.69
Endometrioid carcinoma 46 265.72 ± 207.94 138.46 ± 84.95 89.86 ± 49.37
Cell differentiation <0.05 <0.05 <0.05
High and Medium 88 104.58 ± 83.86 123.86 ± 90.22 87.45 ± 55.36
Low 72 363.29 ± 239.63 378.29 ± 197.34 255.64 ± 158.12
Tumor stage <0.05 <0.05 <0.05
Low stage 74 113.31 ± 96.05 128.73 ± 85.59 73.59 ± 40.64
High stage 86 364.37 ± 243.92 388.61 ± 216.33 247.38 ± 146.55
Nodal status <0.05 <0.05 <0.05
Positive 83 353.94 ± 214.37 376.48 ± 225.64 268.93 ± 117.32
Negative 77 101.55 ± 86.81 131.45 ± 99.56 92.78 ± 61.19
Chen et al. BMC Cancer  (2015) 15:91 Page 9 of 12quiescent cells around them and initiate a cascade of
events resulting in tumor progression. For example,
tumor cell–derived VEGF stimulates the sprouting and
proliferation of endothelial cells. VEGF is considered the
most potent candidate for angiogenesis induction duringFigure 4 Receiver operator characteristic (ROC) curves of
fibulin-4, CA-125 and CA19-9 in patients with ovarian cancer.
The area under the curve (AUC) of fibulin-4, CA-125 and CA19-9
were 0.883, 0.808 and 0.701, suggesting their clinical usefulness for
diagnosing ovarian carcinoma was moderate.tumor growth [43]. Since angiogenesis is essential
for tumor growth and metastasis, controlling tumor-
associated angiogenesis is a promising strategy for
inhibiting cancer progression. In our study, we
sought to determine whether fibulin-4 is associated
with angiogenesis. So the Pearson correlation coeffi-
cient was calculated to assess the correlation of
fibulin-4 with MVD and VEGF expression. We found
that fibulin-4 expression was positively correlated
with MVD and VEGF expression, and the expres-
sions of fibulin-4 and VEGF were both much higher
in highly invasive subclones than in low invasive
subclones, which indicated that fibulin-4 might pro-
mote angiogenesis. No earlier studies on fibulin-4
had reported an association with tumor angiogenesis,
although its highly homologous proteins, fibulin-3
and fibulin-5 were found to be associated with tumor
angiogenesis. For example, exogenous and endogenous
fibulin-5 was shown to be anti-angiogenic [44]. Fibulin-3
was initially found to exert antiangiogenic effect [45], but
in recent years, some studies had reported that fibulin-3
could promote angiogenesis, especially in pancreatic
adenocarcinoma and cervical cancer, they found that
fibulin-3 gene transfection elevated VEGF expression and
microvessel density [17,18]. Since fibulin-4 is highly hom-
ologous to fibulin-3 and fibulin-5, we speculate that
Table 5 Comparison of the diagnostic performance of serum fibulin-4, CA-125, CA19-9, fibulin-4 + CA-125,
fibulin-4 + CA19-9, CA-125 + CA19-9 and fibulin-4 + CA-125 + CA19-9








fibulin-4 75.0 84.0 88.2 67.7 4.69 0.30
CA-125 70.6 79.0 84.3 62.7 3.36 0.37
CA19-9 61.3 70.0 76.6 53.0 2.04 0.55
fibulin-4 + CA-125 68.8 92.0 93.2 64.8 8.59 0.34
fibulin-4 + CA19-9 60.6 90.0 90.6 58.8 6.06 0.44
CA-125 + CA19-9 56.3 88.0 88.2 55.7 4.69 0.50
fibulin-4 + CA-125 + CA19-9 52.5 98.0 97.7 56.3 26.25 0.48
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Pearson correlation tests of MVD and VEGF expression
versus the corresponding expression of fibulin-4 revealed
strong direct correlations. At the same time, as with
fibulin-4, VEGF was also highly expressed in highly inva-
sive subclones. These results partly validated our specula-
tion that fibulin-4 might promote cervical tumor
angiogenesis. Of course, further studies are needed to con-
firm our speculation, such as vascular formation test, nude
mice test, RNAi experiment, etc.
CA125 is one of the most important biomarkers for
ovarian cancer. It is often used for monitoring treatment
effect and detecting recurrence in ovarian cancer.Figure 5 Immunohistochemical staining of VEGF and CD34 for MVD.
carcinoma (A), and high differentiation of ovarian carcinoma (B). (Magnifica
differentiation of ovarian carcinoma (C), and high differentiation of ovarianElevated levels of CA125 have also been found in benign
conditions such as endometriosis, pregnancy, ovulatory
cycles, liver diseases, congestive heart failure, and infec-
tious disease such as tuberculosis. CA125 alone is not a
useful diagnostic marker for ovarian cancer [46,47].
CA19-9 is initially recognized as a marker for human
colon cancer and pancreatic cancer [48,49]. Reports have
showed that CA19-9 is also significantly elevated in pa-
tients with ovarian cancer, especially in mucinous cysta-
denocarcinoma [50]. In our research, high serum levels
of fibulin-4, CA-125 and CA19-9 were all found in ovar-
ian carcinoma when compared with healthy control and
benign ovarian tumor, and high fibulin-4, CA-125 andImmunohistochemical staining of VEGF in low differentiation of ovarian
tion × 200). Immunohistochemical staining of CD34 for MVD in low
carcinoma (D). (Magnification × 200).
Figure 6 Pearson correlations analysis of fibulin-4 expression
with MVD and VEGF. The expression of fibulin-4 positively
correlated with MVD (A) and VEGF (B).
Chen et al. BMC Cancer  (2015) 15:91 Page 11 of 12CA19-9 levels were associated with low differentiation,
advanced stage and positive lymph node status in ovar-
ian carcinomas. Fibulin-4 combined with CA-125 and
CA19-9 lead to a superior diagnostic specificity, positive
predictive value and positive likelihood ratio. In recent
years, fibulins have been recognized as biomarkers for
many diseases, such as osteoarthritis, pleural mesotheli-
oma and breast carcinoma. Fibulin-3 and fibulin-4 may
play pathogenic roles in osteoarthritis [51,33]. The
plasma fibulin-3 and fibulin-1 levels were elevated in pa-
tients with mesothelioma and breast carcinoma, respect-
ively [52,53]. Newer specific biomarkers can help detect
diseases at an earlier stage and tailor treatment strategies
for individualized management. Combined with CA-125
and CA19-9, fibulin-4 may be advantageous to the early
detection of ovarian carcinoma.
Conclusion
Fibulin-4 is a newly identified gene that is overexpressed
in ovarian cancer and associated with poor prognosis.
Combined with CA-125 and CA19-9, serum levels of
fibulin-4 may be helpful to early diagnosis and prognosis
judgment. Fibulin-4 may possibly also serve as a novel
therapeutic target in patients with ovarian cancer in the
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